Title
Research landscape of precision medicine in cardiology
Authors
Shrinidhi Sivasubramaniam1, Keerthika Muniasamy2, L. Elakkiya1, Sanjit Pradeep3, D. Rohan1, S. Yogesh4,*, Sree Nithish Kanna Baskaran5 & Kaarthik Akash Srikanth6
Affiliation
1Institute of Internal Medicine, Madras Medical College, Chennai, India; 2Department of Surgery, Madras Medical College, Chennai, India; 3Department of Internal Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, India; 4Institute of Internal Medicine, Madras Medical College and RGGGH, Chennai and MHPE SCHOLAR, Sri Balaji Vidyapeeth, Pondicherry, India; 5Duty Medical Officer, ICU, SRM Global Hospitals, Kattankulathur, Tamil Nadu, India; 6Department of Internal Medicine, Thanjavur Medical College, Thanjavur, India; *Corresponding author
Shrinidhi Sivasubramaniam - E-mail: shrinidhisiva2020@gmail.com; Phone: +91 9363100725
Keerthika Muniasamy - E-mail: keerthimmc23@gmail.com; Phone: +91 9886601301
L Elakkiya - E-mail: elakkiya0909@gmail.com; Phone: +91 9994993801
Sanjit Pradeep - E-mail: sanjit.pradeep@gmail.com; Phone: +91 9444038064
D Rohan - E-mail: rohan2004.d@gmail.com; Phone: +91 9600855321
S Yogesh - E-mail: yeswhy20@gmail.com; Phone: +91 9600128033
Sree Nithish Kanna Baskaran - E-mail: nithishkanna98@gmail.com; Phone: +91 7092662166
Kaarthik Akash Srikanth - E-mail: kaarthikakash@gmail.com; Phone: +91 9751114734
Article Type
Review
Date
Received July 1, 2025; Revised July 31, 2025; Accepted July 31, 2025, Published July 31, 2025
Abstract
Precision medicine in cardiology integrates genomic, proteomic, and phenotypic data to tailor prevention, diagnosis, and treatment strategies for individual patients. Recent advances have identified genetic variants associated with arrhythmias, cardiomyopathies, and coronary artery disease, enabling risk stratification and targeted therapies. High-throughput “omics” technologies and machine-learning algorithms have facilitated the discovery of novel biomarkers and have refined phenotypic subgroups within heterogeneous cardiac disorders. Pharmacogenomic profiling has demonstrated potential to optimize drug selection and dosing, reducing adverse events and improving therapeutic efficacy. Despite these breakthroughs, challenges such as data integration, clinical implementation barriers, and ethical considerations remain. Ongoing efforts in large-scale consortia, real-world data registries, and adaptive clinical trial designs are expanding the evidence base. This review synthesizes the current research landscape, highlights emerging technologies, and discusses future directions for personalized cardiovascular care.
Keywords
Precision cardiology; genomic medicine; pharmacogenomics; biomarkers; machine learning; personalized therapy; cardiovascular phenotyping
Citation
Sivasubramaniam et al. Bioinformation 21(7): 1886-1890 (2025)
Edited by
A Prashanth
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
